Abstract:In a large cohort (n=77), we characterized the molecular, clinicopathological, and prognostic characteristics of H3 K27M‐mutant spinal cord diffuse glioma. ATRX mutation, CDK6 amplification, RB pathway alteration, a higher number of Copy number variant (CNV) events, chromosome (Chr) 9p deletion, and Chr 10p deletion is associated with worse survival. Glioblastoma histological type and a high Ki‐67 index (>10%) are associated with a worse prognosis. Interestingly, the histological type, an independent prognostic factor in multivariate Cox regression, can stratify molecular features of H3 K27M‐mutant spinal cord glioma, including the RB pathway and PI3K pathway. H3 K27‐altered diffuse midline glioma is a highly lethal pediatric‐type tumor without efficacious treatments. Recent findings have highlighted the heterogeneity among diffuse midline gliomas with different locations and ages. Compared to tumors located in the brain stem and thalamus, the molecular and clinicopathological features of H3 K27‐altered spinal cord glioma are still largely elusive, thus hindering the accurate management of patients. Here we aimed to characterize the clinicopathological and molecular features of H3 K27M‐mutant spinal cord glioma in 77 consecutive cases. We found that the H3 K27M‐mutant spinal cord glioma, with a median age of 35 years old, had a significantly better prognosis than H3 K27M‐mutant brain tumors. We noticed a molecular heterogeneity of H3 K27M‐mutant spinal cord astrocytoma via targeted sequencing with 34 cases. TP53 mutation which occurred in 58.8% of cases is mutually exclusive with PPM1D (26%) and NF1 (44%) mutations. The TP53‐mutant cases had a significantly higher number of copy number variants (CNV) and a marginally higher proportion of pediatric patients (age at diagnosis 10%) are associated with a worse prognosis. Interestingly, the histological type, an independent prognostic factor in multivariate Cox regression, can also stratify molecular features of H3 K27M‐mutant spinal cord glioma, including the RB pathway, KRAS/PI3K pathway, and chromosome arms CNV. In conclusion, although all H3 K27M‐mutant spinal cord diffuse glioma were diagnosed as WHO Grade 4, the histological type, molecular features representing chromatin instability, and molecular alterations associated with accelerated cell proliferative activity should not be ignored in clinical management.

Cnsc-18. A Scoping Review Of Histone 3.3 G34R/V High-Grade Glioma: Epigenetic And Molecular Profiles, Clinicopathology, And Treatment Avenues

Epigenetically defined therapeutic targeting in H3.3G34R/V high-grade gliomas

Path-05. Clinical, Pathological And Molecular Disease Characteristics Of Diffuse Hemispheric Glioma, H3 G34-Mutant

Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies

Radiological and Immunostaining Characteristics of H3.3 G34R-Mutant Glioma: A Report of 3 Cases and Review of the Literature

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Pediatric High-Grade Gliomas

Genomic profiling and prognostic factors of H3 K27M‐mutant spinal cord diffuse glioma

PDTM-31. INVESTIGATING THE EFFECT OF H3G34V MUTATION ON DISTINCT GENOMIC H3K36 METHYLATION PATTERNS IN PEDIATRIC GLIOMA

The Biological Behavior of High-Grade Glioma in H3K27M Mutant Circumscribed Midline Gliomas

Epigenetics to clinicopathological features: a bibliometric analysis of H3 G34-mutant diffuse hemispheric glioma literature

H3K27me3 Loss in Central Nervous System Tumors: Diagnostic, Prognostic, and Therapeutic Implications

Pediatric diffuse midline glioma H3K27- altered: A complex clinical and biological landscape behind a neatly defined tumor type

Biom-43. Somatictp53, Pik3R1, Nf1 Ortert Mutations Are Associated With Inferior Clinical Outcome In H3K27M-Altered Diffuse Midline Glioma: An International, Multi-Institutional Study

METB-01. EFFECTS OF H3.3G34V MUTATION ON GENOMIC H3K36 AND H3K27 METHYLATION PATTERNS IN ISOGENIC PEDIATRIC GLIOMA CELLS

HGG-26. H3G34V MUTATION AFFECTS GENOMIC H3K36 METHYLATION IN PEDIATRIC GLIOMA

Antisense oligonucleotide therapy for H3.3K27M diffuse midline glioma

Targeting SWI/SNF ATPases in H3.3K27M diffuse intrinsic pontine gliomas

Pediatric Diffuse Midline Glioma H3K27-Altered: From Developmental Origins to Therapeutic Challenges

Epco-41. The Nucleosome Remodeling And Deacetylase Complex Underlies Selective Dependency In H3 G34-Mutant Diffuse Hemispheric Glioma

Diffuse Isocitrate Dehydrogenase–Mutant Gliomas With Histone H3 Alterations Are Distinguished by Unique Clinical Characteristics, Molecular Expression Profile, and Survival Prognosis

GABAergic neuronal lineage development determines clinically actionable targets in diffuse hemispheric glioma, H3G34-mutant